Phase 1b:~Patients with advanced solid malignant tumor (including SCLC, NSCLC, colorectal carcinoma, hepatocellular carcinoma, ovarian cancer, neuroendocrine tumors, non-Hodgkin's lymphoma, or etc.) that has relapsed from or is refractory to standard therapy or for which no standard therapy exists will be enrolled in three cohorts (35 mg, 50 mg, and 65 mg).~After screening, eligible patients will be enrolled sequentially in 3 dose-escalating cohorts. Based on an estimated average body weight of 60 kg, the initial dose of chiauranib will be 35 mg once daily, and the dose will be escalated to 50 mg and 65 mg once daily, depending on the occurrence and frequency of DLTs. The 3+3 design will be employed in dose escalation decisions. The 50 mg dose cohort will not enroll until the 35 mg is deemed safe. The same for the 65 mg dose cohort, it will not enroll until the 50 mg is deemed safe.~Each dose cohort will enroll at least 3 patients. Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period, as described below. DLTs will be evaluated during this period (a total of 34 days).~Phase 2:~SCLC patients with progressive disease or recurrence after at least 2 previous regimens, including one platinum-based chemotherapy, will be enrolled in this stage. The RP2D will be given to all patients enrolled in this stage. Patients will take the RP2D chiauranib once daily for 28-day cycles continuously with no interruption between cycles.
This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages:~Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods)~Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.